staurosporine has been researched along with Hematologic Malignancies in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griffin, JD; Manley, PW; Sattler, M; Weisberg, E | 1 |
| Pardanani, A | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Champain, K; Csermak, K; Fabbro, D; Fletcher, L; Ganeshaguru, K; Hart, S; Jones, D; Man, A; Mehta, A; Meyer, T; Prentice, HG; Virchis, A; Wickremasinghe, R; Wright, F; Yap, A | 1 |
| Cheson, BD | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
| Adelsperger, J; Anderson, KC; Chen, J; Coburn, A; Cohen, S; Duclos, N; Fabbro, D; Gilliland, DG; Griffin, JD; Huntly, BJ; Kutok, JL; Lee, BH; Mitsiades, CS; Moore, S; Okabe, R; Williams, IR | 1 |
| Senderowicz, AM | 1 |
| Belka, C; Berdel, WE; Kreuter, M; Los, M; Renz, A; Schulze-Osthoff, K | 1 |
3 review(s) available for staurosporine and Hematologic Malignancies
| Article | Year |
|---|---|
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Management; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Survival Analysis; Transplantation, Homologous; Tryptases | 2019 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Topics: Alkaloids; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; Piperidines; Retinoblastoma Protein; Signal Transduction; Staurosporine | 2001 |
1 trial(s) available for staurosporine and Hematologic Malignancies
| Article | Year |
|---|---|
A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Hematologic Neoplasms; Humans; Lymphocyte Count; Lymphoproliferative Disorders; Male; Middle Aged; Protein Kinase C; Staurosporine | 2002 |
5 other study(ies) available for staurosporine and Hematologic Malignancies
| Article | Year |
|---|---|
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies
Topics: Antineoplastic Agents; Biological Products; Drug Approval; Hematologic Neoplasms; Humans; Protein Kinase Inhibitors; Staurosporine; Streptomyces | 2018 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Topics: Animals; Bone Marrow Transplantation; Cell Line, Tumor; Disease Models, Animal; Growth Inhibitors; Hematologic Neoplasms; Lymphoma, B-Cell; Mice; Multiple Myeloma; Myeloproliferative Disorders; Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 3; Recombinant Fusion Proteins; Staurosporine; Thanatophoric Dysplasia; Transfection | 2005 |
Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo.
Topics: Adult; Aged; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Biomarkers; Biomarkers, Tumor; Chick Embryo; Cysteine Proteinase Inhibitors; Cytochrome c Group; Cytosol; Dactinomycin; Enzyme Inhibitors; Extracellular Space; Female; Hematologic Neoplasms; Humans; Hydrogen Peroxide; Jurkat Cells; L Cells; L-Lactate Dehydrogenase; Male; Mice; Middle Aged; Mitochondria; Necrosis; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; Protein Transport; Staurosporine; Tumor Necrosis Factor-alpha | 2001 |